CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, The company announced that its wholly-owned subsidiary established in 2020, Advance Cancer Centre Pte. Ltd., has changed its name to CytoMed International Pte. Ltd. (“CytoMed International”), effective May 6, 2026.
The name change reflects the Company’s renewed focus on exploring opportunities to expand its international footprint, including setting up joint ventures overseas, development of international medical tourism initiatives, appointment of overseas representatives and enhancing its profile overseas. Initial geographical focus will be in Asia, especially China.
CytoMed International’s sole asset currently consists of a 19.0% equity interest in a licenced clinic in Malaysia, with an option to increase its shareholding in the future.
The name change does not affect the CytoMed International’s legal entity, ownership structure, or existing contractual obligations.
More details regarding the company’s international business plan will be provided as soon as possible. Meanwhile the Company will use its internal resources to support CytoMed International’s operations.
Media Contact:
Ms Evelyn
CytoMed Therapeutics Ltd
Singapore
https://www.cytomed.sg/
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.
